Abbvie reports on Humira study for chronic skin disease
AbbVie, a Chicago-based company with a research and development facility in Worcester, announced Thursday that results from a Phase 3 study demonstrate that its arthritis drug, Humira is effective in reducing common symptoms in moderate to severe hidradentis supperativa (HS), a chronic skin disease that impacts about 1 percent of the population.
Currently there are no approved treatment options available for sufferers of HS, according to AbbVie.
According to the drug manufacturer, results from the study presented at the 44th Annual European Society for Dermatological Research (ESDR) Meeting in Copenhagen, Denmark, show that moderate-to-severe HS patients treated with Humira at a 40 mg weekly dose achieved a significantly greater response versus those on placebo at week 12.
Results from a second Phase 3 study will be presented at an upcoming medical congress, the company said.
WBJ Web Partners
Most Recent
Most Recent
0 Comments